No headlines found.
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
PRNewswire (Tue, 27-Feb 6:54 PM ET)
PRNewswire (Thu, 22-Feb 4:01 PM ET)
PRNewswire (Thu, 8-Feb 4:15 PM ET)
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Dynavax Technologies trades on the NASDAQ stock market under the symbol DVAX.
As of April 17, 2024, DVAX stock price declined to $11.43 with 2,329,462 million shares trading.
DVAX has a beta of 0.32, meaning it tends to be less sensitive to market movements. DVAX has a correlation of 0.01 to the broad based SPY ETF.
DVAX has a market cap of $1.50 billion. This is considered a Small Cap stock.
Last quarter Dynavax Technologies reported $56 million in Revenue and $.00 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.01.
In the last 3 years, DVAX stock traded as high as $21.39 and as low as $7.09.
The top ETF exchange traded funds that DVAX belongs to (by Net Assets): IJR, XBI, VTI, IWM, FBT.
DVAX has underperformed the market in the last year with a price return of +2.8% while the SPY ETF gained +23.0%. DVAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.4% and -7.1%, respectively, while the SPY returned +5.7% and -3.5%, respectively.
DVAX support price is $11.31 and resistance is $11.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVAX stock will trade within this expected range on the day.